QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
QQQ   290.80 (-1.84%)
AAPL   143.01 (-2.00%)
MSFT   242.26 (-2.38%)
META   147.61 (-2.72%)
GOOGL   96.90 (-2.49%)
AMZN   100.56 (-1.64%)
TSLA   167.73 (-5.72%)
NVDA   192.41 (-5.52%)
NIO   12.01 (-5.51%)
BABA   111.78 (-5.58%)
AMD   72.53 (-3.81%)
T   20.10 (+0.75%)
MU   61.92 (-3.05%)
F   12.89 (-2.86%)
CGC   2.86 (-2.39%)
GE   80.78 (-2.94%)
DIS   107.93 (-1.47%)
AMC   4.99 (-9.44%)
PFE   43.40 (-0.89%)
PYPL   80.03 (-2.20%)
NFLX   353.20 (-2.10%)
NASDAQ:VCEL

Vericel - VCEL Stock Forecast, Price & News

$27.15
-1.38 (-4.84%)
(As of 01/30/2023 03:37 PM ET)
Add
Compare
Today's Range
$27.12
$28.45
50-Day Range
$21.09
$29.54
52-Week Range
$17.30
$43.97
Volume
85,451 shs
Average Volume
464,850 shs
Market Capitalization
$1.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$36.20

Vericel MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.60 Rating Score
Upside/​Downside
33.2% Upside
$36.20 Price Target
Short Interest
Bearish
12.79% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Vericel in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$1.08 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($0.45) to ($0.15) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.65 out of 5 stars

Medical Sector

888th out of 1,049 stocks

Biological Products, Except Diagnostic Industry

147th out of 170 stocks


VCEL stock logo

About Vericel (NASDAQ:VCEL) Stock

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Stock News Headlines

HC Wainwright Reiterates Buy Rating for Vericel (NASDAQ:VCEL)
Vericel (NASDAQ:VCEL) Lifted to "Hold" at StockNews.com
"We need batteries. Literally everywhere."
Pretty much every technological megatrend today requires batteries. That includes EVs... 5G... AI... charging stations... and smart energy storage systems. Find out why the U.S. just added graphite to a list of super-critical minerals, calling it "essential for America's National Defense."
The Next Big Crisis Is Here
You just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.
Vericel Third Quarter 2022 Earnings: Misses Expectations
Vericel Reports Third Quarter 2022 Financial Results
See More Headlines
Receive VCEL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vericel and its competitors with MarketBeat's FREE daily newsletter.

VCEL Company Calendar

Last Earnings
11/09/2022
Today
1/30/2023
Next Earnings (Estimated)
2/23/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VCEL
Employees
281
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$36.20
High Stock Price Forecast
$45.00
Low Stock Price Forecast
$25.00
Forecasted Upside/Downside
+33.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.60
Research Coverage
5 Analysts

Profitability

Net Income
$-7,470,000.00
Pretax Margin
-11.55%

Debt

Sales & Book Value

Annual Sales
$156.18 million
Book Value
$3.64 per share

Miscellaneous

Free Float
44,767,000
Market Cap
$1.28 billion
Optionable
Optionable
Beta
1.83

Social Links


Key Executives

  • Dominick C. Colangelo
    President, Chief Executive Officer & Director
  • Michael HalpinMichael Halpin
    Chief Operating Officer
  • Joseph A. Mara
    Chief Financial Officer & Treasurer
  • Jonathan Mark HopperJonathan Mark Hopper
    Chief Medical Officer
  • Sean C. FlynnSean C. Flynn
    Secretary, Senior Vice President & General Counsel













VCEL Stock - Frequently Asked Questions

Should I buy or sell Vericel stock right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VCEL shares.
View VCEL analyst ratings
or view top-rated stocks.

What is Vericel's stock price forecast for 2023?

5 analysts have issued 12-month target prices for Vericel's shares. Their VCEL share price forecasts range from $25.00 to $45.00. On average, they expect the company's share price to reach $36.20 in the next twelve months. This suggests a possible upside of 26.9% from the stock's current price.
View analysts price targets for VCEL
or view top-rated stocks among Wall Street analysts.

How have VCEL shares performed in 2023?

Vericel's stock was trading at $26.34 at the start of the year. Since then, VCEL shares have increased by 8.3% and is now trading at $28.53.
View the best growth stocks for 2023 here
.

When is Vericel's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our VCEL earnings forecast
.

How were Vericel's earnings last quarter?

Vericel Co. (NASDAQ:VCEL) issued its quarterly earnings results on Wednesday, November, 9th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by $0.02. The biotechnology company earned $38.55 million during the quarter, compared to the consensus estimate of $40.02 million. Vericel had a negative trailing twelve-month return on equity of 10.41% and a negative net margin of 11.36%.

What guidance has Vericel issued on next quarter's earnings?

Vericel issued an update on its FY 2022 earnings guidance on Saturday, January, 28th. The company provided EPS guidance of for the period. The company issued revenue guidance of $164.00 million-$165.00 million, compared to the consensus revenue estimate of $164.62 million.

What is Nick Colangelo's approval rating as Vericel's CEO?

6 employees have rated Vericel Chief Executive Officer Nick Colangelo on Glassdoor.com. Nick Colangelo has an approval rating of 49% among the company's employees. This puts Nick Colangelo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Vericel own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Vericel investors own include Exelixis (EXEL), Novavax (NVAX), Hello Group (MOMO), Dynavax Technologies (DVAX), Synergy Pharmaceuticals (SGYP), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Verastem (VSTM), Amarin (AMRN) and NVIDIA (NVDA).

What is Vericel's stock symbol?

Vericel trades on the NASDAQ under the ticker symbol "VCEL."

Who are Vericel's major shareholders?

Vericel's stock is owned by many different retail and institutional investors. Top institutional shareholders include Scout Investments Inc. (0.72%), Comerica Bank (0.49%), Allspring Global Investments Holdings LLC (0.34%), Yousif Capital Management LLC (0.06%), Maryland State Retirement & Pension System (0.04%) and Natixis Advisors L.P. (0.03%). Insiders that own company stock include Dominick Colangelo, Jonathan Mark Hopper, Jonathan Siegal, Michael Halpin, Paul K Wotton, Robert L Md Zerbe, Sean C Flynn and Steven C Gilman.
View institutional ownership trends
.

How do I buy shares of Vericel?

Shares of VCEL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vericel's stock price today?

One share of VCEL stock can currently be purchased for approximately $28.53.

How much money does Vericel make?

Vericel (NASDAQ:VCEL) has a market capitalization of $1.35 billion and generates $159.26 million in revenue each year. The biotechnology company earns $-7,470,000.00 in net income (profit) each year or ($0.39) on an earnings per share basis.

How many employees does Vericel have?

The company employs 281 workers across the globe.

How can I contact Vericel?

Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.vcel.com. The biotechnology company can be reached via phone at (617) 588-5555, via email at ir@vcel.com, or via fax at 617-588-5554.

This page (NASDAQ:VCEL) was last updated on 1/30/2023 by MarketBeat.com Staff